Vortex Liquid Biopsy Solutions has been selected to represent the Cambridge x Manchester Partnership at Cambridge Tech Week 2026, following a highly competitive application process involving innovative companies from across the UK technology and life sciences sectors.
Vortex will join a select cohort of businesses chosen to showcase the strength of the Cambridge-Manchester innovation ecosystem to investors, corporates, policymakers, researchers and industry leaders attending Cambridge Tech Week on 16 September.
The selection reflects growing recognition of Vortex’s work in advancing liquid biopsy technologies for precision oncology. The company’s proprietary platform enables the label-free isolation and analysis of intact circulating tumour cells (CTCs) from a routine blood sample, supporting applications in cancer diagnostics, biomarker discovery, drug development and treatment monitoring.
Dr Paul Reeves, Managing Director of Vortex Liquid Biopsy Solutions, said:
“We are delighted to have been selected to represent the Cambridge x Manchester Partnership at Cambridge Tech Week 2026. This is a significant endorsement of both our technology and the progress Vortex has made in advancing functional liquid biopsy solutions for precision oncology.”
“Cambridge Tech Week provides a valuable opportunity to engage with investors, pharmaceutical companies, researchers and innovation leaders from across the UK and internationally. We look forward to showcasing how Vortex is helping unlock clinically actionable insights from circulating tumour cells.”
The announcement comes during a period of increasing momentum for the company, following Vortex’s selection as the first participant in the AstraZeneca Exchange Programme. Together, these endorsements reflect the company’s growing profile within the UK life sciences ecosystem.
As part of the event, Vortex will meet with investors, industry partners and potential collaborators while demonstrating the capabilities of its liquid biopsy platform and discussing opportunities to accelerate the adoption of next-generation cancer diagnostic technologies.
